These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30625410)

  • 1. A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes.
    Glicksman R; Sanmamed N; Thoms J; Zlotta AR; Finelli A; van der Kwast T; Sweet J; Jewett M; Klotz LH; Rosewall T; Fleshner NE; Bristow RG; Warde P; Berlin A
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):61-66. PubMed ID: 30625410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer.
    Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
    Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
    Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer.
    Koontz BF; Quaranta BP; Pura JA; Lee WR; Vujaskovic Z; Gerber L; Haake M; Anscher MS; Robertson CN; Polascik TJ; Moul JW
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):88-93. PubMed ID: 23790772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformal postoperative radiotherapy in patients with positive resection margins and/or pT3-4 prostate adenocarcinoma.
    Bellavita R; Massetti M; Abraha I; Lupattelli M; Mearini L; Falcinelli L; Farneti A; Palumbo I; Porena M; Aristei C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e299-304. PubMed ID: 22572075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
    Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
    Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy for early-stage prostate cancer in men under 70 years of age.
    Bellavita R; Scricciolo M; Bini V; Arcidiacono F; Montesi G; Lancellotta V; Zucchetti C; Lupattelli M; Palumbo I; Aristei C
    Tumori; 2016; 102(2):209-16. PubMed ID: 26429649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy.
    Ost P; Cozzarini C; De Meerleer G; Fiorino C; De Potter B; Briganti A; Nagler EV; Montorsi F; Fonteyne V; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):960-5. PubMed ID: 22172901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.
    Tandberg DJ; Oyekunle T; Lee WR; Wu Y; Salama JK; Koontz BF
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):396-405. PubMed ID: 29559284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial.
    Qi X; Li HZ; Gao XS; Qin SB; Zhang M; Li XM; Li XY; Ma MW; Bai Y; Li XY; Wang D
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):282-290. PubMed ID: 31669564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy.
    Pearse M; Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw A; Cheung P
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):792-8. PubMed ID: 18707818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
    Zelefsky MJ; Kelly WK; Scher HI; Lee H; Smart T; Metz E; Schwartz L; Fuks Z; Leibel SA
    J Clin Oncol; 2000 May; 18(9):1936-41. PubMed ID: 10784635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late genitourinary toxicity in salvage radiotherapy for prostate cancer after radical prostatectomy: impact of daily fraction doses.
    Takano S; Tomita N; Takaoka T; Niwa M; Torii A; Kita N; Okazaki D; Uchiyama K; Nakanishi-Imai M; Ayakawa S; Iida M; Tsuzuki Y; Otsuka S; Manabe Y; Nomura K; Ogawa Y; Miyakawa A; Miyamoto A; Takemoto S; Yasui T; Hiwatashi A
    Br J Radiol; 2024 May; 97(1157):1050-1056. PubMed ID: 38466928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.